NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

NRx Pharmaceuticals (NASDAQ: NRXP) will present updates on its business at the H.C. Wainwright BioConnect Virtual Conference on January 10, 2022, at 7:00 AM EST. The company is known for developing the BriLife™ vaccine and ZYESAMI® for COVID-19. It has received Fast Track designation from the FDA and is conducting Phase 3 trials for various treatments, including NRX-101 for bipolar depression. The presentation link is available here.

• Conference Begins on January 10, 2022

RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be presenting updates to the Company’s business at the H.C. Wainwright BioConnect Virtual Conference.

Details of the presentation can be found below:

Date: Monday, January 10, 2022

Time: 7:00 AM EST

Link to Presentation: https://journey.ct.events/view/1464b340-bd79-4a96-ae16-572a470d569b

About NRx Pharmaceuticals

NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. The Company is developing the BriLife™ Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense. NRx is additionally developing ZYESAMI® (aviptadil) for patients with COVID-19, and has been granted Fast Track designation by the US Food and Drug Administration (FDA), and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022.

NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA. NRx is chaired by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in six biotechnology startup companies with public exits and been appointed to advisory roles in four US Presidential Administrations. The NRx board includes Dr. Sherry Glied, former US Assistant Secretary for Health (ASPE), Daniel E. Troy, JD, former Chief Counsel of the US FDA, Chaim Hurvitz, former director of Teva and President of the Teva International Group, and General H.R. McMaster, Ph.D. (US Army, Ret.) the 26th United States National Security Advisor.

Cautionary Note Regarding Forward-Looking Statements

This announcement of NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company’s strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company’s management.

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

CORPORATE CONTACT:
Jack Hirschfield – Head of Corporate Communications, NRx
jhirschfield@nrxpharma.com

INVESTOR RELATIONS
Eric Goldstein
Managing Director – LifeSci Advisors
egoldstein@lifesciadvisors.com

FAQ

When will NRx Pharmaceuticals present at the H.C. Wainwright BioConnect Conference?

NRx Pharmaceuticals will present on January 10, 2022, at 7:00 AM EST.

What is the link to the NRx Pharmaceuticals presentation?

You can access the presentation at this link: Presentation Link.

What is NRx Pharmaceuticals developing for COVID-19?

NRx Pharmaceuticals is developing the BriLife™ COVID vaccine and ZYESAMI® for patients with COVID-19.

What designations has ZYESAMI® received from the FDA?

ZYESAMI® has received Fast Track designation from the FDA and is undergoing Phase 3 trials.

What is NRX-101 and its current status?

NRX-101 is an investigational medicine for treating suicidal bipolar depression and is currently in Phase 3 trials.